On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets
Executive Summary
Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.
You may also be interested in...
Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating
Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.
Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating
Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.
APA Update: New Antidepressants Elbow Into Crowded Market
Lundbeck/Takeda unveil pivotal trial data for Brintellix (vortioxetine) in major depression, while Forest pooled analyses shed more light on levomilnacipran in subgroups. Docs don’t think the new drugs are differentiated, but since antidepressant response is so quirky, the prescribing door is still open.